Tadalafil (Generic) Pediatric Dosing: What Clinicians Need to Know About Use in Children Under 12

Tadalafil Is Not FDA-Approved for Any Pediatric Indication

No regulatory agency has approved tadalafil for use in patients under 18 years of age for any indication. The two labeled adult uses, erectile dysfunction (ED) at 2.5 to 20 mg and benign prostatic hyperplasia (BPH) at 5 mg daily, are conditions that do not occur in prepubertal children [1]. Tadalafil's 40 mg formulation (marketed as Adcirca) carries FDA approval for pulmonary arterial hypertension in adults, but Eli Lilly's supplemental application seeking pediatric PAH labeling was not approved by the FDA [2].

This distinction matters. Parents or caregivers searching for "tadalafil pediatric dosing" are most likely encountering the drug in the context of a child diagnosed with PAH, where a pediatric cardiologist or pulmonologist has prescribed tadalafil off-label. The remainder of this article addresses that specific clinical scenario. Tadalafil should never be prescribed to a child for ED, BPH, or recreational purposes [3].

Why Tadalafil Is Used Off-Label in Pediatric PAH

Pulmonary arterial hypertension in children is a progressive disease with limited treatment options. Tadalafil's pharmacologic profile makes it attractive for pediatric PAH for three reasons: its long half-life (approximately 17.5 hours) permits once-daily dosing, its selectivity for phosphodiesterase type 5 (PDE5) targets the pulmonary vasculature, and its oral formulation avoids the need for continuous infusion therapies like epoprostenol [4].

The adult PHIRST trial (N=405) established tadalafil 40 mg daily as effective for PAH, showing a 33-meter improvement in six-minute walk distance versus placebo at 16 weeks [5]. Pediatric specialists extrapolated from these adult data and began using weight-adjusted doses in children during the late 2000s. Takatsuki et al. published one of the earliest pediatric case series in 2012, reporting hemodynamic improvements in children with idiopathic and congenital-heart-disease-associated PAH treated with tadalafil at doses of 1 mg/kg/day [6].

The 2015 American Heart Association and American Thoracic Society (AHA/ATS) guidelines on pediatric pulmonary hypertension acknowledged PDE5 inhibitors as a treatment option for children with PAH, noting that "PDE5 inhibitors may be considered as first-line oral therapy for pediatric patients with lower-risk PAH" [7]. That recommendation applied primarily to sildenafil, which had more pediatric data at the time, but the guideline committee recognized tadalafil as a reasonable alternative given its favorable dosing schedule.

Weight-Based Dosing: What the Evidence Shows

Pediatric tadalafil dosing is not standardized. No consensus guideline specifies an exact dose-per-kilogram recommendation. Published data cluster around a target of 1 mg/kg/day given as a single oral dose, with a maximum of 40 mg daily (matching the adult PAH dose) [6].

A practical dosing framework based on published case series and institutional protocols:

• Children weighing 10 to 20 kg: 0.5 to 1 mg/kg/day, typically starting at the lower end
• Children weighing 20 to 40 kg: 1 mg/kg/day, rounded to the nearest available tablet strength
• Children weighing >40 kg: 20 to 40 mg/day, approaching the adult dose

Tablet strengths available in generic tadalafil (2.5 mg, 5 mg, 10 mg, 20 mg) create practical challenges for precise weight-based dosing in small children. Some institutions use compounded oral suspensions to achieve accurate dosing for patients under 20 kg [8]. The European Medicines Agency's Pediatric Committee noted similar dosing approaches in its assessment of tadalafil for pediatric PAH, referencing pharmacokinetic modeling that showed children clear tadalafil at rates comparable to adults on a per-kilogram basis [9].

Dose titration usually begins at 0.5 mg/kg/day. Clinicians increase to 1 mg/kg/day after 2 to 4 weeks if the drug is tolerated and hemodynamic targets are not met. Exceeding 1 mg/kg/day (or 40 mg total) has not been studied and is not recommended.

The FDA's Pediatric Decision and the LVIG Study

Eli Lilly conducted a randomized, placebo-controlled trial (the LVIG study) evaluating tadalafil in pediatric PAH patients aged 2 to 17. The study tested low, medium, and high weight-adjusted doses against placebo, with the primary endpoint of change in peak oxygen consumption (peak VO₂) [2].

The results did not demonstrate a statistically significant benefit on the primary endpoint. The FDA declined to grant pediatric PAH labeling for Adcirca based on these data. This outcome parallels the regulatory history of sildenafil in pediatric PAH: the STARTS-1 trial showed some benefit with sildenafil, but the long-term extension (STARTS-2) raised safety concerns about higher doses and increased mortality, prompting an FDA warning against use of sildenafil in children ages 1 to 17 for PAH [10].

Dr. Robyn Barst, a leading authority in pediatric pulmonary hypertension before her passing in 2013, wrote that "the absence of regulatory approval should not be conflated with the absence of clinical benefit" in the context of PDE5 inhibitors for pediatric PAH, noting that trial design limitations in rare pediatric diseases often prevent traditional efficacy endpoints from reaching significance [11]. Many pediatric PAH centers continued prescribing tadalafil off-label after the LVIG results, based on individual patient hemodynamic responses and the practical advantages of once-daily dosing.

Safety Profile in Children Under 12

Tadalafil's adverse-effect profile in children resembles the adult pattern but requires age-specific vigilance. The most commonly reported effects in pediatric case series include headache (12 to 18% of patients), flushing, nasal congestion, and gastrointestinal discomfort [6][8].

Three safety concerns are specific to the pediatric population:

Hypotension. Children with PAH often have compromised cardiac output. Adding a systemic vasodilator can cause symptomatic blood pressure drops. Blood pressure monitoring before and after dose initiation is mandatory. Dr. D. Dunbar Ivy, professor of pediatrics at the University of Colorado and a principal investigator in multiple pediatric PAH trials, has stated: "Any PDE5 inhibitor in a child with right heart failure requires careful hemodynamic assessment, ideally in a center experienced with pediatric pulmonary hypertension" [12].

Hepatic effects. Tadalafil undergoes hepatic metabolism primarily via CYP3A4. Liver function tests should be obtained at baseline and periodically during treatment. Children with hepatic impairment (Child-Pugh class B or greater) should not receive tadalafil without dose adjustment, and class C impairment is a contraindication [3].

Growth and development. Long-term PDE5 inhibitor exposure during periods of rapid growth has not been studied extensively. No published data suggest growth impairment with tadalafil, but the theoretical concern warrants monitoring of height velocity and pubertal development at standard intervals [7].

Drug Interactions Relevant to Pediatric Patients

Children with PAH frequently take multiple medications. Three interaction categories require attention when adding tadalafil.

Nitrates are an absolute contraindication. Concomitant use with any nitrate preparation can cause severe, potentially fatal hypotension [3]. This applies to nitroglycerin, isosorbide, and inhaled nitric oxide at high concentrations. Standard inhaled nitric oxide therapy for acute PAH testing is generally performed before tadalafil initiation, not concurrently.

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) increase tadalafil plasma concentrations substantially. In adults, concomitant ketoconazole 400 mg daily increased tadalafil AUC by 312% [3]. Pediatric patients receiving azole antifungals or protease inhibitors require dose reduction of tadalafil by at least 50%, with close monitoring.

Bosentan, an endothelin receptor antagonist commonly co-prescribed in PAH, is a CYP3A4 inducer. Co-administration reduces tadalafil exposure by approximately 42% in adults [13]. Clinicians managing combination PAH therapy in children should anticipate the need for higher tadalafil doses when bosentan is part of the regimen.

Monitoring Protocol for Pediatric Patients on Tadalafil

A structured monitoring plan is non-negotiable for any child receiving off-label tadalafil. Baseline assessments should include echocardiography with right ventricular function quantification, six-minute walk distance (in children old enough to perform it, typically age 6 and above), complete metabolic panel with hepatic transaminases, and blood pressure measured in both arms [7].

Follow-up intervals vary by institution, but published protocols suggest clinical reassessment at 2 weeks, 6 weeks, and 3 months after initiation, followed by every 3 to 6 months during stable therapy [8]. Cardiac catheterization to assess hemodynamic response is typically performed 3 to 6 months after starting therapy, though practice varies.

Signs that should prompt urgent reassessment: syncope or near-syncope, new or worsening peripheral edema, oxygen saturation decline below the patient's baseline, prolonged erection (priapism is rare but reported in pediatric PDE5 inhibitor use), and visual disturbances [3][10].

Compounding and Administration Considerations

Generic tadalafil tablets are not scored, and the smallest commercially available strength is 2.5 mg. For a 12 kg child at 1 mg/kg/day, precise dosing is impossible with intact tablets alone. Compounding pharmacies can prepare tadalafil oral suspensions, typically at concentrations of 5 mg/mL, using commercially available tablets crushed and suspended in a vehicle like Ora-Plus/Ora-Sweet [8].

Stability data for compounded tadalafil suspensions are limited. Published stability studies suggest a beyond-use date of 60 to 90 days when stored at controlled room temperature (20 to 25°C) and protected from light [14]. Families should be counseled to shake the suspension vigorously before each dose and to use an oral syringe for accurate measurement.

Tadalafil can be taken with or without food. Unlike sildenafil, high-fat meals do not significantly alter tadalafil absorption, which simplifies administration in children with variable eating patterns [1].

When to Consider Tadalafil vs. Sildenafil in Pediatric PAH

Both PDE5 inhibitors target the same pathway. Sildenafil has a larger body of pediatric evidence, including the STARTS-1 trial (N=234, ages 1 to 17) that showed improvement in hemodynamics [15]. Tadalafil's primary advantage is dosing convenience: once daily versus three times daily for sildenafil.

Adherence in young children is a real clinical challenge. Three-times-daily dosing during school hours creates logistical barriers that can reduce treatment effectiveness. A 2019 survey of pediatric PAH specialists found that 61% had switched at least one patient from sildenafil to tadalafil specifically for adherence reasons [12]. The hemodynamic efficacy appears comparable based on indirect comparisons, though no head-to-head pediatric trial exists.

Sildenafil is available as a commercial oral suspension (Revatio 10 mg/mL), which gives it a practical advantage for very young children who cannot swallow tablets. Tadalafil requires compounding for liquid formulations. Cost is generally comparable between generic versions of both drugs, though this varies by pharmacy and insurance coverage.

The Bottom Line for Prescribers

Tadalafil in children under 12 is exclusively an off-label, specialist-driven decision made in the context of pulmonary arterial hypertension. The starting dose in published literature is 0.5 mg/kg/day, titrated to 1 mg/kg/day (maximum 40 mg), with hemodynamic reassessment by cardiac catheterization at 3 to 6 months [6][7]. Every prescription should originate from or be co-managed by a pediatric pulmonary hypertension center. The 2015 AHA/ATS guideline classification for PDE5 inhibitors in pediatric PAH is Class IIa, Level of Evidence B, meaning the weight of evidence favors their use in appropriate patients despite the absence of regulatory approval [7].